NCIC CTG Abstractsto be presented at: 42ndAnnual ASCO Meeting June 2nd – June 6th, 2006, Atlanta, Georgia

Saturday, June 3rd, 2006
8:00 - 1:00 pm
Poster Discussion
Bldg B, Level 4, RoomB401
Breast Cancer I / NCIC CTG MA.17: Intent to treat analysis of random-ized patients after a median follow-up of 54 months
Presenter: James Ingle
Poster #: 12 / Abstract No: 549
Updated analysis of NCIC CTG MA.17 (letrozole vs. placebo to letrozole vs placebo) post unblinding
Presenter: Nicholas J. Robert
Poster #: 13 / Abstract No: 550
8:00 am – 1:00
Poster Discussion
Bldg A, Level 3, RoomA314
Lung Cancer I / Class III beta tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: Analysis of the national Cancer Institute of Canada Clinical Trials Group study JBR.10
Presenter: Tony Reiman
Poster #: 20 / Abstract No: 7051
3:00 pm – 6:00
Oral Presentation
Bldg C, Level 1, HallC2
Lung Cancer I / Adjuvant chemotherapy in elderly patients: An analysis of National Cancer Institute of Canada Clinical Trials Group and Intergroup BR.10
Presenter: Carmela Pepe
3:30 – 3:45 pm / Abstract No: 7009
2:00 pm – 6:00
General Poster Session
Bldg B, Level 1, HallB5 / The prognostic effects of performance status and quality of life scores on progression-free survival and overall survival in advanced ovarian cancer (OV.10)
Presenter: Mark S. Carey
Poster #: N8 / Abstract No: 5066
Gynecologic Cancer
Sunday, June 4th, 2006
10:00 - 11:30 am
Clinical Science Symposium
Bldg C, Level 1
HallC2
Are Epidermal
Growth Factor / An analysis of the prognostic and predictive importance of K-ras mutation status in the National Cancer Institute of Canada Clinical Trials Group BR.21 study of erlotinib versus placebo in the treatment of non-small cell lung cancer
Presenter: Ming-Sound Tsao
10:45 – 11:00 am / Abstract No: 7005
Receptor Biomarkers Getting UsCloser to or Further from the Target?
8:00 - 12:00 pm
Poster Discussion
Bldg B, Level 4, RoomB401
Gastrointestinal / Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer. A meta-analysis of two randomized trials (CO.7)
Presenter: Emmanuel Mitry
Poster #: 12 / Abstract No: 3524
(Colorectal) Cancer
8:00 am – 12:00
General Poster Session
Bldg B, Level 1, HallB5
Lung Cancer / Identifying patients with non-small cell lung cancer unlikely to benefit from erlotinib: An exploratory analysis of National Cancer Institute of Canada Clinical Trials Group BR.21
Presenter: Marie Florescu
Poster #: R5 / Abstract No: 7161
An economic analysis of National Cancer Institute of Canada Clinical Trials Group JBR.10, a randomized trial of adjuvant vinorelbine plus cisplatin versus observation in early stage non-small cell lung cancer
Presenter: Raymond Ng
Poster #: Q11 / Abstract No: 7155
Are age and comorbidity independent prognostic factors in the treatment of metastatic NSCLC? A review of prospectively randomized National Cancer Institute of Canada Clinical Trials Group trials
Presenter: Timothy R. Asmis
Poster #: M10 / Abstract No: 7117
2:00 – 6:00 pm
General Poster Session
Bldg B, Level 1, HallB5
Developmental
Therapeutics: / Final results of a phase I study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor receptors, in combination with carboplatin + paclitaxel in patients with advanced non-small cell lung cancer: A study of the NCIC Clinical Trials Group (IND.171)
Presenter: Scott A. Laurie
Poster #: X8 / Abstract No: 3054
Molecular Therapeutics
Monday, June 5, 2006
8:00 - 12:00pm
General Poster Session
Bldg B, Level 1, HallB5
Health Services Research / Early closure of clinical trials: The experience of the National Cancer Institute of Canada Clinical Trials Group
Presenter: Wendy Parulekar
Poster #: G6 / Abstract No: 6053
Use of placebo in cancer medicine: The experience of a National Clinical Trials organization
Presenter: Joseph L. Pater
Poster #: L5 / Abstract No: 6104
8:00 - 9:30 am
Clinical Science Symposium
Bldg A, Level 4
Sidney J. Marcus Auditorium / Molecular correlates associated with a phase II study of temsirolimus (CCI-779) in patients with metastatic or recurrent endometrial cancer – NCIC IND 160
Presenter: Amit M. Oza
8:45 – 9:00 am / Abstract No: 3003
2:00 - 6:00 pm
Poster Discussion
Bldg C, Level 3, RoomC306
Lymphoma and / Bortezomib is active in Waldenström’s Macroglobulinemia (WM) – Results of a National Cancer Institute of Canada phase II study in previously untreated or treated WM (IND.152)
Presenter: Christine I. Chen
Poster #: 19 / Abstract No: 7543
Plasma Cell Disorders
9:00 - 12:15 pm
Oral Presentation
Bldg C, Level 1, HallC1
Breast Cancer II / Left ventricular function following adjuvant chemotherapy for breast cancer: The NCIC CTG MA5 experience
Presenter: Lois E. Shepherd
10:00 – 10:15 am / Abstract No: 522
Insulin resistance, estimated by serum C-peptide level, is associated with reduced event-free survival for postmenopausal women in NCIC CTG MA.14 adjuvant breast cancer trial
Presenter: Michael N. Pollak
10:45 – 11:00 am / Abstract No: 524
3:00 pm – 6:00
Oral Presentation
Bldg C, Level 1, HallC4
Gastrointestinal (Colorectal) Cancer / Routine short course pre-op radiotherapy or selective post-op chemoradiotherapy for resectable rectal cancer? Preliminary results of the MRC CR07 randomised trial (CO.16)
Presenter: David Sebag-Monefiore
5:15 – 5:30 pm / Abstract No: 3511
Local recurrence after rectal cancer resection is strongly related to the plane of surgical dissection and is further reduced by pre-operative short course radiotherapy. Preliminary results of the Medical Research Council (MRC) CR07 trial (CO.16)
Presenter: Phillip Quirke
5:30 – 5:45 pm / Abstract No: 3512
Tuesday, June 6, 2006
8:00 –9:15 pm
Educational Session
Bldg C, Level 3,Georgia Ballroom2
Comparisons of / Canadian Perspective on Bi-Directional Collaboration, with Europe and with US
Presenter: Joseph L. Pater
United States and International Clinical Trials: What Can We Learn?
9:00 - 12:00 pm
Oral Presentation
Bldg C, Level 1, HallC1
Breast Cancer III / Prognostic and predictive value of topoisomerase II alpha in a randomized trial comparing CMF to CEF in premenopausal women with node positive breast cancer (NCIC CTG MA.5)
Presenter: Frances P. O’Malley
10:15 – 10:30 am / Abstract No: 533
8:00 - 12:00 pm
Poster Discussion
Bldg A, Level 3, RoomA314 / NCIC CTG MA.17: Tolerability of letrozole among ethnic minority women
Presenter: Beverly Moy
Poster #: 8 / Abstract No: 6018
Health Services Research